TRAVERE THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
TRAVERE THERAPEUTICS, INC. (TVTX) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$2.81M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$6.12M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$15.78M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$12.93M, a 133.76% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | -$1.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | -$1.47M derived: sum of 3 quarters · filed 2026-08-04 | -$2.81M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.47M derived: sum of 2 quarters · filed 2026-08-04 | -$2.81M 10-Q · filed 2025-10-30 | -$3.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$2.81M 10-Q · filed 2026-08-04 | -$3.37M derived: sum of 3 quarters · filed 2026-08-04 | -$5.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$1.35M 10-Q · filed 2026-05-04 | -$1.91M derived: sum of 2 quarters · filed 2026-05-04 | -$3.82M derived: sum of 3 quarters · filed 2026-05-04 | -$5.94M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$559.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.47M derived: sum of 2 quarters · filed 2026-02-19 | -$4.59M derived: sum of 3 quarters · filed 2026-02-19 | -$6.12M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$4.04M derived: sum of 2 quarters · filed 2025-10-30 | -$5.56M 10-Q · filed 2025-10-30 | -$11.14M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.64M 10-Q · filed 2025-08-06 | -$9.22M derived: sum of 3 quarters · filed 2026-02-19 | -$12.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$1.52M 10-Q · filed 2025-05-01 | -$7.10M derived: sum of 2 quarters · filed 2026-02-19 | -$10.48M derived: sum of 3 quarters · filed 2026-02-19 | -$13.46M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$8.96M derived: sum of 2 quarters · filed 2026-02-19 | -$11.94M derived: sum of 3 quarters · filed 2026-02-19 | -$15.78M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$6.36M derived: sum of 2 quarters · filed 2024-10-31 | -$10.20M 10-Q · filed 2024-10-31 | -$14.23M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$6.82M 10-Q · filed 2024-08-01 | -$10.85M derived: sum of 3 quarters · filed 2025-02-21 | -$14.05M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$3.84M 10-Q · filed 2024-05-06 | -$7.88M derived: sum of 2 quarters · filed 2025-02-21 | -$11.07M derived: sum of 3 quarters · filed 2025-02-21 | -$14.63M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$7.23M derived: sum of 2 quarters · filed 2025-02-21 | -$10.78M derived: sum of 3 quarters · filed 2025-02-21 | -$12.93M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$6.75M derived: sum of 2 quarters · filed 2023-11-07 | -$8.90M 10-Q · filed 2023-11-07 | -$10.75M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.70M 10-Q · filed 2023-08-03 | -$7.55M derived: sum of 3 quarters · filed 2024-02-20 | $32.60M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$2.15M 10-Q · filed 2023-05-04 | -$4.00M derived: sum of 2 quarters · filed 2024-02-20 | $36.15M derived: sum of 3 quarters · filed 2024-02-20 | $36.15M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $38.30M derived: sum of 2 quarters · filed 2024-02-20 | $38.30M derived: sum of 3 quarters · filed 2024-02-20 | $38.30M 10-K · filed 2024-02-20 |
| 2021-09-30 | $40.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $40.15M derived: sum of 2 quarters · filed 2022-10-27 | $40.15M 10-Q · filed 2022-10-27 | $40.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-10-29 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |